ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright on strong NSCLC trial data
Investing.com
Published Jun 30, 2025 07:40AM ET
Investing.com - H.C. Wainwright has reiterated a Buy rating and $40.00 price target on ArriVent BioPharma (NASDAQ:AVBP) following updated results from the company's Phase 1b FURTHER trial evaluating firmonertinib in first-line EGFR PACC-positive non-small cell lung cancer patients. The $784 million market cap company currently trades at $22.91, with analyst targets ranging from $37 to $45, according to InvestingPro data.
The trial demonstrated a best objective response rate (ORR) of 52.2% at the 160mg daily dose and 81.8% at the 240mg daily dose, with confirmed ORRs of 43.5% and 68.2% respectively, as assessed by blinded independent central review. Responses were observed across both common and less frequent EGFR PACC mutations, including single and compound mutations. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 14.34, providing ample resources for continued clinical development.
The data showed strong efficacy in patients with brain metastases, with 53% (9/17) of these patients achieving a confirmed central nervous system ORR, including a 41% complete response rate. The median duration of response has not been reached, with most responding patients continuing in the study.
Median progression-free survival reached 11.1 months for the 160mg dose group and 16.0 months for the 240mg dose group. The safety profile showed grade 3 or higher treatment-related adverse events in 20% of patients at the 160mg dose and 22.7% at the 240mg dose.
H.C. Wainwright analyst Robert Burns noted these results compare favorably to historical data for EGFR PACC mutations, where first-, second-, and third-generation tyrosine kinase inhibitors demonstrated ORRs of 37.2%, 59.6%, and 46.3%, respectively, while acknowledging upcoming competitive data from Black Diamond Therapeutics (NASDAQ:BDTX) and ORIC Pharma. With an overall Financial Health score of "Good" and strong cash position relative to debt, InvestingPro data suggests ArriVent is well-positioned to advance its clinical programs.
In other recent news, ArriVent BioPharma has announced promising results from its Phase 1b FURTHER trial, revealing a 16-month median progression-free survival for patients treated with firmonertinib for non-small cell lung cancer (NSCLC) with EGFR PACC mutations. The company reported a 68.2% confirmed overall response rate at the 240 mg dose level, with a median duration of response of 14.6 months. Additionally, the drug displayed significant efficacy in patients with brain metastases, achieving a 41% complete response rate. ArriVent plans to advance firmonertinib to a global Phase 3 trial, aiming for potential accelerated and full approval.
Analyst firm H.C. Wainwright has raised the price target for ArriVent BioPharma to $40, maintaining a Buy rating, following these encouraging clinical trial results. The analyst highlighted firmonertinib's strong outcomes compared to existing treatments and its potential to fill a treatment gap for NSCLC patients with specific genetic mutations. Furthermore, ArriVent BioPharma has appointed Dr. Merdad Parsey to its Board of Directors, bringing extensive experience in global clinical development during a critical phase for the company. Dr. Parsey's appointment aligns with ArriVent's strategy to advance its therapeutic pipeline, including firmonertinib and next-generation antibody drug conjugates.
Get The News You Want
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.